Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-08-01

Clinical Trial Update: Zurig (Febuxostat) 40mg Efficacy and Safety Trial [Phase 4]

View source ↗

Summary

Phase 4 trial updating the efficacy and safety of Zurig (Febuxostat) 40 mg for hyperuricemia has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Zurig (Febuxostat)

Snippet

Sponsor: Getz Pharma | Conditions: Hyperuricemia | Phase 4 | Status: COMPLETED